CGEN

Compugen Ltd (CGEN) | Rumor.io

Compugen

CGEN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,253

Bullish sentiment (50-day avg)71%

Price to earnings ratio6.3

Market capitalization220.7M

Earnings per share0.37

Dividend yield (TTM)—

Revenue (annual)72.8M

Net income (annual)35.3M

Social

What share of all stock conversation is about CGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

May 18

Compugen Ltd.'s Q1 2026 update reported a cash runway into 2029, with $134.9M in cash and no debt, supporting its clinical-stage burn and modest revenue.
The company's key trials are progressing, including COM701 in ovarian cancer, AstraZeneca's rilvegostomig in multiple Phase 3s, and the Gilead partnered program.
Compugen's Q1 2026 earnings reported revenue of $2.2M, down -4.4% Y/Y, with a GAAP EPS of -$0.08, but highlighted a highly resilient balance sheet.

Generated by AI

Sentiment

Of the messages about CGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	29.63% -44.14	79.22% -14.46
Bearish	—	—	70.37% +44.14	20.78% +14.46

Bullish· Mar 2

$CGEN is expected to break past the $2.40 resistance level and blast even higher, with a massive breakout expected.
Compugen Ltd.'s recent earnings report was a significant surprise, with a 3000% and 900% upside in earnings and revenue, respectively.
The company's strong financial position, flush with cash and no debt, combined with its good pipeline and big Pharma relationships, make it a promising investment opportunity.

Bearish· Dec 20

The market is showing high volume, with Compugen Ltd. trading 430% above average, indicating a possible sell-off.
The stock's current price and market cap do not reflect potential future cash flows, with the company barely covering short-term cash payments.
Compugen Ltd. is experiencing a gap down, which could be a sign of capitulation, and may be due for a gap fill, potentially leading to further price drops.

Generated by AI

Topics

Of the messages about CGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	76.86%
Technical Analysis	—	—	—	11.35%
Controversies	—	—	—	0.22%
Analysts	—	—	—	9.17%
Earnings	—	—	—	2.4%
Macro	—	—	—	0%

Earnings· Feb 21

Compugen $CGEN reported FQ4 earnings of -18c EPS and $0M in revenue.
$CGEN missed the Estimize EPS consensus by 1c and the Estimize revenue consensus by $0.79M.
The company's stock price increased by +6.56% following the release of its Q4 earnings results.

Announcements· Dec 17

Compugen Ltd. has monetized a portion of its Rilvegostomig future royalties to AstraZeneca for up to $90 million, providing a significant cash infusion and extending its cash runway into 2029.
The deal involves an upfront payment of $65 million, with up to $25 million tied to a BLA milestone, and Compugen retains the majority of its future royalties.
The transaction is expected to strengthen Compugen's balance sheet and support its research and development efforts, with the company's shares trading higher following the announcement.

Technical Analysis· Dec 19

$CGEN is forming a bull pennant and may break out soon.
The stock needs to hold $2 support to stay bullish, with accumulation zones moved between $2.11 and $2.13.
A break above $2.20 or $2.24 could lead to a major move to the upside, with some traders expecting a price target of $2.70+.

Generated by AI

Community

Of the messages about CGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	18.5%	37.04%
Newcomers	100%	100%	81.5%	62.96%

Regulars· Dec 19

Compugen has entered an exclusive license agreement with Gilead for its pre-clinical immunotherapy program against IL-18, with Gilead paying $60 million upfront and potentially $10 million in a near-term milestone payment.
Compugen's share price has surged due to the deal, with a 48939% increase in trading volume and a 164.42% price rise, potentially saving the company from NASDAQ delisting.
Compugen will host a conference call to discuss the exclusive license agreement with Gilead, which will focus on the novel pre-clinical program harnessing IL-18 biology and the COM503 drug candidate.

Newcomers· Dec 17

Compugen has partnered with AstraZeneca, potentially earning up to $90 million from future royalties for the Rilvegostomig drug.
The deal strengthens Compugen's balance sheet and extends its cash runway into 2029, providing a significant financial boost to the company.
The stock price has experienced significant fluctuations in the short-term, making it a high-risk investment opportunity for traders and investors.

Generated by AI

News

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

8d agoYahoo Finance

Compugen Shareholders Approve All Proposals at 2026 Annual Meeting

Detailed price information for Compugen Ltd (CGEN-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held from September 14-16 in New York City.

22d agoYahoo Finance

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

29d agoYahoo Finance

Are Medical Stocks Lagging Compugen (CGEN) This Year?

Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.

1mo agoYahoo Finance

Compugen (CGEN) Q2 2026 Earnings Call Transcript

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about CGEN also mention

#	Name	Attention
1	Arcus Biosciences, Inc.RCUS	0%new
2	Cerus CorporationCERS	0%new
3	Evogene Ltd.EVGN	0%new
4	PBLA - Panbela Therapeutics, Inc.	——
5	C4 Therapeutics IncCCCC	0.01%new
6	Shattuck Labs, Inc.STTK	0%new
7	Sera Prognostics, Inc. Class A Common StockSERA	0%0
8	SURF - Surface Oncology, Inc.	——
9	Syros Pharmaceuticals Inc.SYRS	0%0
10	F/m US Treasury 7 Year Note ETFUSVN	0%0

Compugen Ltd

Healthcare
Biotechnology

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases. Compugen Ltd. uses its AI- and machine learning-powered Unigen platform to identify novel drug targets, validate biological pathways, and advance therapeutic and diagnostic biomarker candidates. Its current work centers on developing antibodies and other biologic product candidates for oncology and immune-related conditions, with programs designed to address unmet needs in solid tumors and inflammatory diseases. The company operates across Israel, the United States, and Europe, supporting research, development, and commercial collaboration activities. Headquartered in Holon, Israel, Compugen Ltd. plays a role in the biotechnology market as a platform-driven company that combines computational discovery with experimental development to build differentiated drug candidates.

Website

Location

Azrieli Center

Holon, 5885849

Israel

Social

What share of all stock conversation is about CGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

May 18

Compugen Ltd.'s Q1 2026 update reported a cash runway into 2029, with $134.9M in cash and no debt, supporting its clinical-stage burn and modest revenue.
The company's key trials are progressing, including COM701 in ovarian cancer, AstraZeneca's rilvegostomig in multiple Phase 3s, and the Gilead partnered program.
Compugen's Q1 2026 earnings reported revenue of $2.2M, down -4.4% Y/Y, with a GAAP EPS of -$0.08, but highlighted a highly resilient balance sheet.

Generated by AI

Sentiment

Of the messages about CGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	29.63% -44.14	79.22% -14.46
Bearish	—	—	70.37% +44.14	20.78% +14.46

Bullish· Mar 2

$CGEN is expected to break past the $2.40 resistance level and blast even higher, with a massive breakout expected.
Compugen Ltd.'s recent earnings report was a significant surprise, with a 3000% and 900% upside in earnings and revenue, respectively.
The company's strong financial position, flush with cash and no debt, combined with its good pipeline and big Pharma relationships, make it a promising investment opportunity.

Bearish· Dec 20

The market is showing high volume, with Compugen Ltd. trading 430% above average, indicating a possible sell-off.
The stock's current price and market cap do not reflect potential future cash flows, with the company barely covering short-term cash payments.
Compugen Ltd. is experiencing a gap down, which could be a sign of capitulation, and may be due for a gap fill, potentially leading to further price drops.

Generated by AI

Topics

Of the messages about CGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	76.86%
Technical Analysis	—	—	—	11.35%
Controversies	—	—	—	0.22%
Analysts	—	—	—	9.17%
Earnings	—	—	—	2.4%
Macro	—	—	—	0%

Earnings· Feb 21

Compugen $CGEN reported FQ4 earnings of -18c EPS and $0M in revenue.
$CGEN missed the Estimize EPS consensus by 1c and the Estimize revenue consensus by $0.79M.
The company's stock price increased by +6.56% following the release of its Q4 earnings results.

Announcements· Dec 17

Compugen Ltd. has monetized a portion of its Rilvegostomig future royalties to AstraZeneca for up to $90 million, providing a significant cash infusion and extending its cash runway into 2029.
The deal involves an upfront payment of $65 million, with up to $25 million tied to a BLA milestone, and Compugen retains the majority of its future royalties.
The transaction is expected to strengthen Compugen's balance sheet and support its research and development efforts, with the company's shares trading higher following the announcement.

Technical Analysis· Dec 19

$CGEN is forming a bull pennant and may break out soon.
The stock needs to hold $2 support to stay bullish, with accumulation zones moved between $2.11 and $2.13.
A break above $2.20 or $2.24 could lead to a major move to the upside, with some traders expecting a price target of $2.70+.

Generated by AI

Community

Of the messages about CGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	18.5%	37.04%
Newcomers	100%	100%	81.5%	62.96%

Regulars· Dec 19

Compugen has entered an exclusive license agreement with Gilead for its pre-clinical immunotherapy program against IL-18, with Gilead paying $60 million upfront and potentially $10 million in a near-term milestone payment.
Compugen's share price has surged due to the deal, with a 48939% increase in trading volume and a 164.42% price rise, potentially saving the company from NASDAQ delisting.
Compugen will host a conference call to discuss the exclusive license agreement with Gilead, which will focus on the novel pre-clinical program harnessing IL-18 biology and the COM503 drug candidate.

Newcomers· Dec 17

Compugen has partnered with AstraZeneca, potentially earning up to $90 million from future royalties for the Rilvegostomig drug.
The deal strengthens Compugen's balance sheet and extends its cash runway into 2029, providing a significant financial boost to the company.
The stock price has experienced significant fluctuations in the short-term, making it a high-risk investment opportunity for traders and investors.

Generated by AI

Compugen

Social

May 18

Bullish· Mar 2

Bearish· Dec 20

Earnings· Feb 21

Announcements· Dec 17

Technical Analysis· Dec 19

Regulars· Dec 19

Newcomers· Dec 17

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

Compugen Shareholders Approve All Proposals at 2026 Annual Meeting

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

Are Medical Stocks Lagging Compugen (CGEN) This Year?

Compugen (CGEN) Q2 2026 Earnings Call Transcript

Also Discussed

Compugen Ltd

Company Information

Location

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

Compugen Shareholders Approve All Proposals at 2026 Annual Meeting

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

Are Medical Stocks Lagging Compugen (CGEN) This Year?

Compugen (CGEN) Q2 2026 Earnings Call Transcript

Also Discussed

Social

May 18

Bullish· Mar 2

Bearish· Dec 20

Earnings· Feb 21

Announcements· Dec 17

Technical Analysis· Dec 19

Regulars· Dec 19

Newcomers· Dec 17